Skip to search.
 TSX Down 0.72% TSX Ventures Down 0.44%

Celgene Corporation (CELG)

-NasdaqGS
107.93 Up 0.41(0.38%) 4:00PM EDT
|After Hours : 107.65 Down 0.28 (0.26%) 4:08PM EDT - Nasdaq Real Time Price
Prev Close:107.52
Open:107.87
Bid:107.84 x 1200
Ask:107.85 x 300
1y Target Est:135.82
Beta:1.60011
Next Earnings Date:28-Jul-16CELG Earnings announcement
Day's Range:106.73 - 108.14
52wk Range:92.98 - 136.40
Volume:2,750,182
Avg Vol (3m):4,365,150
Market Cap:83.60B
P/E (ttm):52.50
EPS (ttm):2.06
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
CELGUp 0.38%83.60B
JNJDown 0.11%343.53B

Key Statistics

Forward P/E (1 yr):15.36
P/S (ttm):8.60
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :5.70
Quarterly EPS Est (Jun-16) :1.38
Mean Recommendation*:1.9
PEG Ratio (5 yr expected):0.86

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback